Immunomagnetic enrichment of disseminated tumor cells in bone marrow and blood of breast cancer patients by the Thomsen-Friedenreich-Antigen

Purpose The presence of disseminated tumor cells in the bone marrow (DTC-BM) of breast cancer patients has shown independent prognostic impact. Immunomagnetic enrichment of such cells is an approach to increase the number of detected cells with limited sample volume, especially for circulating tumor cells (CTCs) in blood. The Thomsen-Friedenreich (TF) antigen (CD 176) is a specific oncofetal carbohydrate epitope (Galβ1-3GalNAcα-O) expressed on the surface of various carcinomas. Own studies demonstrated a nearly complete TF expression on DTC-BM, indicating its suitability as marker for immunomagnetic enrichment. Methods BM samples of 65 and peripheral blood samples of 11 breast cancer patients were examined immunocytochemically by staining with the anti-Cytokeratin antibody A45-B/B3 before and after immunomagnetic enrichment. Enrichment was done by incubation with the primary antibody TF 2 (IgM), followed by secondary magnetically labelled rat-anti mouse IgM. Cytospin slides were screened manually by bright-field microscopy. Results 15/65 pts (23%) showed DTC-BM in primary screening with a median of 2/2 mio cells (range 1–10). By enrichment, a median of 23.3 mio cells (0.8–218) could be analysed, increasing positivity to 72% (47/65 pts) with a med. of 4 DTCs (1–105, P < .0001). Blood from 1/11 pts before and 5/11 (45%) after enrichment showed CTCs (med. 2, 1–20), at a med. of 12.4 mio (2.6–38.5) cells analysed. Comparing BM and blood of the same patients after enrichment, 5 were positive in both compartments, 4 showed DTC-BM without presence of CTCs. Conclusion The positive immunomagnetic enrichment technique with TF-antibodies enables to analyse larger sample volumes and increase tumor cell detection rate. This could allow monitoring and characterisation of CTCs as targets for therapies.

[1]  I. Takanami.  Expression of Thomsen-Friedenreich antigen as a marker of poor prognosis in pulmonary adenocarcinoma. , 1999, Oncology reports.

[2]  T. Fehm,et al.  A pooled analysis of bone marrow micrometastasis in breast cancer. , 2005, The New England journal of medicine.

[3]  M B Flamm.  Detection of breast cancer. , 1987, JAMA.

[4]  Tanja Fehm,et al.  Circulating Tumor Cells in Patients with Breast Cancer Dormancy , 2004, Clinical Cancer Research.

[5]  T. Dimpfl,et al.  Prognostic significance of an increased number of micrometastatic tumor cells in the bone marrow of patients with first recurrence of breast carcinoma , 2000, Cancer.

[6]  T. Aono,et al.  Tn antigen, a marker of potential for metastasis of uterine cervix cancer cells , 1993, Cancer.

[7]  T. Dimpfl,et al.  Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. , 2000, The New England journal of medicine.

[8]  Kristine R Broglio,et al.  Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden. , 2007, Clinical breast cancer.

[9]  A. Hölscher,et al.  Thomsen‐Friedenreich antigen presents as a prognostic factor in colorectal carcinoma , 2000, Cancer.

[10]  T. Fehm,et al.  A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation , 2006, Cancer.

[11]  S. Krajewski,et al.  Prognostic impact of Thomsen–Friedenreich tumor antigen and disseminated tumor cells in the bone marrow of breast cancer patients , 2006, Breast Cancer Research and Treatment.

[12]  E. Lane,et al.  Conformational changes in the rod domain of human keratin 8 following heterotypic association with keratin 18 and its implication for filament stability. , 2004, Biochemistry.

[13]  M C Miller,et al.  Expression of epithelial cell adhesion molecule in carcinoma cells present in blood and primary and metastatic tumors. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  J. Nesland,et al.  Comparison of the clinical significance of occult tumor cells in blood and bone marrow in breast cancer , 2006, International journal of cancer.

[15]  H Sommer,et al.  Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  H. Taubert,et al.  Detection of disseminated tumor cells in peripheral blood of patients with breast cancer: correlation to nodal status and occurrence of metastases. , 2004, Gynecologic oncology.

[17]  N. Kröger,et al.  Immunomagnetic tumor cell selection—implications for the detection of disseminated cancer cells , 2000, Transfusion.

[18]  D. Mavroudis,et al.  Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  D. Wallwiener,et al.  Rare expression of epithelial cell adhesion molecule on residual micrometastatic breast cancer cells after adjuvant chemotherapy. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  G. T. Budd,et al.  Circulating Tumor Cells at Each Follow-up Time Point during Therapy of Metastatic Breast Cancer Patients Predict Progression-Free and Overall Survival , 2006, Clinical Cancer Research.

[21]  H. Sommer,et al.  Characterisation of disseminated tumor cells in the bone marrow of breast cancer patients by the Thomsen–Friedenreich tumor antigen , 2005, Histochemistry and Cell Biology.

[22]  Thomas Rau,et al.  Circulating Tumor Cells in Breast Cancer: Correlation to Bone Marrow Micrometastases, Heterogeneous Response to Systemic Therapy and Low Proliferative Activity , 2005, Clinical Cancer Research.

[23]  Anne Vincent-Salomon,et al.  Clinical Significance of Immunocytochemical Detection of Tumor Cells Using Digital Microscopy in Peripheral Blood and Bone Marrow of Breast Cancer Patients , 2004, Clinical Cancer Research.

[24]  J. Thiery,et al.  A relevant immunomagnetic assay to detect and characterize epithelial cell adhesion molecule‐positive cells in bone marrow from patients with breast carcinoma , 2004, Cancer.

[25]  R. Coombes,et al.  The clinical significance of disseminated tumor cells in breast cancer , 2007, Nature Clinical Practice Oncology.

[26]  K. Okuno,et al.  Inhibition of Liver Metastases from Neuraminidase-Treated Colon 26 Cells by an Anti-Thomsen-Friedenreich-Specific Monoclonal Antibody , 1999, Tumor Biology.

[27]  K. Pienta,et al.  Intravascular metastatic cancer cell homotypic aggregation at the sites of primary attachment to the endothelium. , 2003, Cancer research.

[28]  Falk Schubert,et al.  Bi-specific immunomagnetic enrichment of micrometastatic tumour cell clusters from bone marrow of cancer patients. , 2005, Journal of immunological methods.

[29]  Claire Holloway,et al.  Enumeration of Circulating Tumor Cells in the Blood of Breast Cancer Patients After Filtration Enrichment: Correlation with Disease Stage , 2004, Breast Cancer Research and Treatment.

[30]  A. Ludwig,et al.  Increased expression of Thomsen-Friedenreich antigens during tumor progression in breast cancer patients. , 1988, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[31]  P. Schlag,et al.  Expression of thomsen‐friedenreich‐related antigens in primary and metastatic colorectal carcinomas. A reevaluation , 1995, Cancer.

[32]  V. Diehl,et al.  Immunomagnetic enrichment and detection of isolated tumor cells in bone marrow of patients with epithelial malignancies , 2002, Clinical & Experimental Metastasis.

[33]  K. Pantel,et al.  Influence of immunomagnetic enrichment on gene expression of tumor cells , 2005, Journal of Translational Medicine.

[34]  B. Naume,et al.  Immunomagnetic techniques for the enrichment and detection of isolated breast carcinoma cells in bone marrow and peripheral blood. , 1997, Journal of hematotherapy.

[35]  M. Delgado-Rodríguez,et al.  Detection of breast cancer cells in the peripheral blood is positively correlated with estrogen‐receptor status and predicts for poor prognosis , 2003, International journal of cancer.

[36]  S Miltenyi,et al.  Immunomagnetic enrichment of disseminated epithelial tumor cells from peripheral blood by MACS. , 1998, Experimental hematology.

[37]  J. Nesland,et al.  Increased sensitivity for detection of micrometastases in bone‐marrow/peripheral‐blood stem‐cell products from breast‐cancer patients by negative immunomagnetic separation , 1998, International journal of cancer.